RENAL INJURY BIOMARKERS AS BIOMARKERS FOR ACUTE HEPATIC PORPHYRIA (AHP)

DIAGNOSTIC AGENT AND MEDICINE COMPRISING ADAMTS13 AS MAIN INGREDIENT

MOLECULAR MARKER FOR DIAGNOSING PRIMARY BILIARY CHOLANGITIS AND METHOD FOR DETECTING SAME

ANTI-APRIL ANTIBODIES AND USES THEREOF

IDENTIFICATION AND USE OF GLYCOPEPTIDES AS BIOMARKERS FOR DIAGNOSIS AND TREATMENT MONITORING

TIMP1 AS A MARKER FOR CHOLANGIOCARCINOMA

Methods for Modulating Bile Acid Homeostasis and Treatment of Bile Acid Disorders and Diseases

DIAGNOSTIC AGENT AND MEDICINE COMPRISING ADAMTS13 AS MAIN INGREDIENT

METHODS OF TREATING LIVER DISEASES

METHODS FOR TREATMENT OF BILE ACID-RELATED DISORDERS AND PREDICTION OF CLINICAL SENSITIVITY TO TREATMENT OF BILE ACID-RELATED DISORDERS

Identification and use of glycopeptides as biomarkers for diagnosis and treatment monitoring

Diagnosis of Liver Pathology Through Assessment of Protein Glycosylation

Screening method for cerebrotendinous xanthomatosis using bile alcohol glucuronides and metabolite ratios

METHODS FOR DIAGNOSIS AND INTERVENTION OF HEPATIC DISORDERS

Diagnostic agent and medicine comprising ADAMTS13 as main ingredient

IDENTIFICATION AND USE OF BIOLOGICAL PARAMETERS FOR DIAGNOSIS AND TREATMENT MONITORING

Biomarkers in autoimmune liver disease

Methods for detecting sinusoidal obstructive syndrome (SOS)

Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders

Galactose oral composition and use thereof

PLASMA AND LIVER LIPID SPECIES AS BIOMARKERS OF FATTY LIVER

METHODS AND SYSTEMS FOR SCREENING CANDIDATE COMPOUNDS FOR THEIR POTENTIAL TO CAUSE SYSTEMIC OR HEPATIC TOXICITY

Methods of Using Compositions Comprising Variants and Fusions of FGF19 Polypeptides for Treatment of Liver Fibrosis

Methods of Using Compositions Comprising Variants and Fusions of FGF19 Polypeptides for Treatment of Cirrhosis

Methods of Using Compositions Comprising Variants and Fusions of FGF19 Polypeptides for Treatment of Nonalcoholic Fatty Liver Disease

Methods for diagnosis and intervention of hepatic disorders

Identification and use of glycopeptides as biomarkers for diagnosis and treatment monitoring

Process for in vitro diagnosis of hepatic disorders

Hepatocytes with high regenerative capacity for liver repair

In vitro production of cholangiocytes

Methods of using compositions comprising variants of FGF19 polypeptides for treating primary biliary cirrhosis in a subject

Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders

Method of screening a candidate compound for inducing bile canalicular function disorders

Diagnosis of liver pathology through assessment of protein glycosylation

Methods for diagnosis and intervention of hepatic disorders

Methods of using compositions comprising variants and fusions of FGF19 polypeptides for treatment of nonalcoholic steatohepatitis

Biomarkers for the identification of liver damage

Methods for diagnosis and intervention of hepatic disorders

Anti-NPC2 monoclonal antibodies and a method of detecting fatty liver tissue, cancer cells or cancer tissue by using them

ASSESSING NON-ALCOHOLIC FATTY LIVER DISEASE

5.9 kDa peptide immunoassay method

DETECTION OF HEPATIC INSULIN RESISTANCE

Method of collecting specimen and method of diagnosing subject to detect upper digestive system disease

DIAGNOSIS OF LIVER PATHOLOGY THROUGH ASSESSMENT OF PROTEIN GLYCOSYLATION

Recognition of CYP2E1 epitopes

COMPOSITIONS, KITS, AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND THERAPY OF HEPATIC DISORDERS

LIVER DISEASE MARKER, METHOD AND APPARATUS FOR MEASURING THE SAME, AND METHOD FOR ASSAYING PHARMACEUTICAL PREPARATION

Glucuronidated Acetaminophen as a Marker of Hepatic Disorders

METHOD OF IMMUNOLOGICAL ANALYSIS FOR DETECTION OF ANTIBODIES AGAINST HUMAN GSTT1 (ANTI-HGSTT1)

Identifying organ damage

METHODS AND KITS FOR DETERMINING THE OCCURRENCE OF A LIVER DISEASE IN A SUBJECT

Diagnosis of liver pathology through assesment of protein glycosylation

Biomarkers for liver diseases and method for using the same

Biomarkers of liver injury

Non-invasive marker for liver function and disease

DIAGNOSIS METHOD FOR FATTY LIVER DISEASE, DIAGNOSIS APPARATUS, DIAGNOSIS PROGRAM, DIAGNOSTIC AGENT, AND METHOD FOR SCREENING FOR THERAPEUTIC AGENT FOR FATTY LIVER DISEASE

Methods for diagnosis and intervention of hepatic disorders

Marker proteins for diagnosing liver disease and method of diagnosing liver disease using the same

ASSESSING NON-ALCOHOLIC FATTY LIVER DISEASE

Diagnosis of liver pathology through assessment of protein glycosylation

USE OF A GLP-1 MOLECULE FOR TREATMENT OF BILIARY DYSKINESIA AND/OR BILIARY PAIN/DISCOMFORT

FATTY ACID SYNTHASE IN LIVER DISEASE

Use of Human Hepatocytes for Determining Liver Function and Liver Regeneration

ULTRAHIGHLY SENSITIVE DETERMINATION REAGENT FOR C-REACTIVE PROTEIN AND DETERMINATION METHOD

Pigment epithelium-derived factor as a therapeutic agent for vascular leakage

Biomarkers for liver diseases and method for using the same

Drugs For Diseases Accompanying Changes In Total Bile Acid Pool Or Lipid Metabolism Disorders And Method Of Screening These Drugs

Method for Diagnosing Hepatic Diseases

Methods of judging non-alcoholic steatohepatitis

Diagnosis of liver pathology through assessment of protein glycosylation

Interleukin-8 homologous polypeptides and therapeutic uses thereof

Non-invasive marker for liver function and disease

Biomarkers of liver injury

Interleukin-8 homologous polypeptides and therapeutic uses thereof

Method for diagnosing liver diseases

Human hepatocyte-like cells and uses thereof

Marker proteins for diagnosing liver disease and method of diagnosing liver disease using the same

Liver disease diagnosis system, method and graphical user interface

Biomarkers for liver diseases and method for using the same

Interleukin-8 homologous polypeptides and therapeutic uses thereof

Kit and method of screening wilson's disease